Premier Fund Managers Ltd Grows Stake in Astrana Health, Inc. (NASDAQ:ASTH)

Premier Fund Managers Ltd boosted its stake in Astrana Health, Inc. (NASDAQ:ASTH) by 67.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,243 shares of the company’s stock after buying an additional 11,009 shares during the quarter. Premier Fund Managers Ltd’s holdings in Astrana Health were worth $871,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Janus Henderson Group PLC acquired a new position in shares of Astrana Health during the third quarter valued at approximately $1,164,000. Principal Financial Group Inc. acquired a new position in Astrana Health in the 3rd quarter valued at $13,383,000. Franklin Resources Inc. purchased a new position in Astrana Health in the 3rd quarter valued at $1,187,000. Geode Capital Management LLC acquired a new stake in Astrana Health during the 3rd quarter worth $58,995,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Astrana Health during the third quarter worth $5,799,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ASTH has been the topic of a number of recent research reports. Bank of America lowered their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Stifel Nicolaus lowered their price objective on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Robert W. Baird cut their target price on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Finally, Truist Financial lowered their price target on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.17.

Astrana Health Stock Up 1.9 %

Shares of ASTH opened at $31.36 on Friday. The company’s 50-day moving average price is $33.95 and its 200 day moving average price is $42.10. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a 12-month low of $23.12 and a 12-month high of $63.20. The firm has a market cap of $1.57 billion, a P/E ratio of 24.12, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. On average, sell-side analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.